Chitosan beads as a new gastroretentive system of verapamil

Scientia Pharmaceutica

Volumn 74, Issue 4, 2006, Pages 175-188

  Yassin, Alaa Eldeen B ^a   Alsarra, Ibrahim A ^a   Al Mohizea, Abdulah M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Chitosan; Controlled release; Floating; Gastro retentive; Verapamil

Indexed keywords

ALDEHYDE DERIVATIVE; CHITOSAN; TRIPOLYPHOSPHATE; VERAPAMIL; WATER;

ARTICLE; DIFFUSION; DIGESTIVE SYSTEM; DRUG DELIVERY SYSTEM; GEOMETRY; HYDROGEL; KINETICS; MOLECULAR WEIGHT; SUSTAINED RELEASE PREPARATION; SYRINGE;

EID: 33846384724     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.2006.74.175     Document Type: Article

References (32)

1. McTavish D, Sorkin E. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1989; 38: 19-76.
2. Frishman W, Rosenberg A, Katz B. Calcium antagonists in the management of systemic hypertension: the impact of sustained-release drug-delivery systems. Coron Artery Dis. 1994; 5: 4-13.
3. Klein H, Kaplinsky E. Digitalis and verapamil in atrial fibrillation and flutter. Is VP now the preferred agent? Drugs. 1986; 31: 185-197.
4. Yusuf S, Held P, Funberg C. Update of effects of calcium antagonists in MI or angina in light of the second Danish infarction trial (Davit II) and other recent studies. Am J Cardiol. 1991; 67: 1295-1297.
5. Tsang Y, Pop R, Gordon P, J. Hems and M. Spino. High variability in drug Pharmacokinetics complicates determination of bioequivalence: experience with verapamil. Pharm Res. 1996; 13: 846-850.
6. Marvola M, Kannikoski A, Taskinen J, Ottoila P. Assessment of bioavailability of experimental single-unit sustained release tablets of verapamil hydrochloride using the stable isotope technique. J Pharm Pharmacology. 1985; 37: 766-770.
7. Jankowski A, Marzec A, Lamparczyk H. Comparative bioavailability of verapamil from rapidly absorbed and slow release preparations. J Pharm Biomed Anal. 1992; 10: 1101-1103.
8. Moës A. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Sys. 1993; 10: 143-195.
9. Yang L, Eshraghi J, Fassihi R. A new intra-gastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in-vitro evaluation. J. Control. Release. 1999; 57: 215-222.
10. Deshpande A, Rhodes C, Shah N, Malick A. Controlled-release drug delivery system for prolonged gastric residence: An overview. Drug Dev Ind Pharm. 1996; 22: 531-539.
11. Caldwell L, Gardner C, Cargill R. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent. 1988; 4, 735,804.
12. Park K, Park H. Enzyme-digestible balloon hydrogels for long-term oral drug delivery: Synthesis and characterization. Proceeding International Symposium Controlled Release Bioactive Materials. 1987; 14: 41-42.
13. Ponchel G, Touchard F, Duchene D, Peppas N. Bioadhesive analysis of controlled release systems: I. Fracture and interpenetration analysis in poly (acrylic acid)-containing systems. J Control Release. 1987; 5: 129-141.
14. Lehr C, Bouwstra J, Tukker J, Junginger H. Intestinal transit of bioadhesive microspheres in an in situ loop in the rat- A comparative study with copolymers and blends based on poly (acrylic acid). J Control Release. 1990; 13: 51-62.
15. Davis S, Stockwell A, Taylor M, Hardy J, Whalley D, Wilson C, Bechgaard H, Christensen F. The effect of density on the gastric emptying of single-and multiple-unit dosage forms. Pharm Res. 1986; 3: 208-213.
16. Graham N. Controlled drug delivery systems. Chem Indust. 1990; 15: 482-486.
17. Struszczyk, H.; Wawro, D.; Niekraszewicz, A. Biodegradability of chitosan fibres, In: Brine CJ, Sandford PA, Zikakis JP (eds), Advances in Chitin and Chitosan, Elsevier Applied Science, London, 1991:580-585.
18. Chandy T, Sharma C. Chitosan-as a biomaterial. Biomat Art Cells Art Org. 1990; 18: 1-24.
19. Hirano, S; Seino, H; Akiyama, Y; Nonaka Y. Chitosan: a biocompatible material for oral and intravenous administrations. In: Gebelein CG, Dunn RL (eds), Progress in Biomedical Polymers, Plenum, New York, 1990: 283-290.
20. Kreuter, J. Nanoparticles. In: Kreuter J (ed), Colloidal Drug Delivery Systems, Marcel Dekker, New York, 1994: 219-342.
21. Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in the controlled drug delivery. Int J Pharm. 1995; 116: 1-9.
22. Bodmeier, R; Paeratakul, O. Suspensions and dispersible dosage forms of multiparticulates. In: Ghebre-Sellassie I (ed), Multiparticulate Oral Drug Delivery, Marcel Dekker, New York. 1994: 143-156.
23. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release. 2003; 89: 151-165.
24. Bodmeier R, Oh K, Pramar Y. Preparation and evaluation of drug containing chitosan beads. Drug Dev Ind Pharm. 1989; 15: 1475-1494.
25. Alsarra I, Betigeri S, Zhang H, Evans B, Neau S. Molecular weight and degree of decatylation effects on lipase-loaded chitosan bead characteristics. Biomaterials. 2002; 23: 3637-3644.
26. Betigeri S, Neau S. Immobilization of lipase using hydrophilic polymers in the form of hydrogel beads. Biomaterials. 2002; 23: 3627-3636.
27. James E, Singh G, Larry L, Vinod P. Method to compare dissolution profiles and a rationale for wide dissolution specification for metoprolol tartrate tablets. J Pharm Sci. 1994; 86: 690-700.
28. Wu P, Tsai M, Huang Y, Chang J, Tsai Y. In vitro and in vivo evaluation of potassium chloride sustained release formulation prepared with polyglycolyed glycerides matrices. Int J Pharm. 1994; 243: 119-124.
29. Korsmeyer R, Gurny R, Doelker E, Buri P, Peppas N. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983; 15: 25-35.
30. Peppas N. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985; 60: 110-111.
31. NTP, Toxicology and carcinogenesis studies of glutaraldehyde (CAS No. 111-30-8) in F344/N rats and B6C3F1 mice (inhalation studies). Natl. Toxicol. Program Tech. Rep. Ser. 490 (1999), pp. 1-234.
32. Garcia-Selles J, Pascual A, Funes E, Pagan J, Lopez J, Negro J, Hernandez J. Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of parietaria judaica. Allergol. Immunopathol. (Madr.). 2003, 31:63-69.